Show
Sort by
-
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND) : an open-label extension study
-
Defining polysaccharide antibody deficiency : measurement of anti-pneumococcal antibodies and anti-Salmonella typhi antibodies in a cohort of patients with recurrent infections
-
A method for comprehensive proteomic analysis of human faecal samples to investigate gut dysbiosis in patients with cystic fibrosis
-
- Journal Article
- A1
- open access
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
-
Faecal proteomics : a tool to investigate dysbiosis and inflammation in patients with cystic fibrosis
-
- Journal Article
- A1
- open access
Primary ciliary dyskinesia : critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure
-
Amoxicillin-clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings
-
- Journal Article
- A1
- open access
Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota
-
Misdiagnosis as asphyxiating thoracic dystrophy and CMV-associated haemophagocytic lymphohistiocytosis in Shwachman-Diamond syndrome
-
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings